S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSE:PRME

Prime Medicine (PRME) Stock Price, News & Analysis

$7.00
+0.24 (+3.55%)
(As of 03/28/2024 ET)
Today's Range
$6.71
$7.06
50-Day Range
$6.35
$9.39
52-Week Range
$5.54
$17.20
Volume
641,716 shs
Average Volume
645,905 shs
Market Capitalization
$839.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.57

Prime Medicine MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
151.0% Upside
$17.57 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.03mentions of Prime Medicine in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.83) to ($1.61) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

312th out of 938 stocks

Biological Products, Except Diagnostic Industry

44th out of 148 stocks

PRME stock logo

About Prime Medicine Stock (NYSE:PRME)

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

PRME Stock Price History

PRME Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Recap: Prime Medicine Q4 Earnings
Prime Medicine GAAP EPS of -$2.18
Thomas Cahill's Net Worth
Stock Offerings Prompt Big Insider Buying
PRME Mar 2024 12.500 call
See More Headlines
Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.57
High Stock Price Target
$26.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+151.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-198,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.37 per share

Miscellaneous

Free Float
90,806,000
Market Cap
$839.58 million
Optionable
Optionable
Beta
1.88
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Keith Michael Gottesdiener Ph.D. (Age 70)
    President, CEO, Secretary & Director
    Comp: $924.04k
  • Dr. Ann L. Lee Ph.D. (Age 62)
    Chief Technical Officer
    Comp: $947.28k
  • Mr. Richard Brudnick (Age 67)
    Chief Business Officer
    Comp: $680.8k
  • Dr. Andrew Anzalone M.D. (Age 37)
    Ph.D., Co-Founder & Head of Prime Editing Platform
  • Dr. David R. Liu Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Allan Reine M.D. (Age 49)
    Chief Financial Officer
  • Dr. Meredith Goldwasser (Age 52)
    Senior VP and Head of Strategy & Corporate Operations
  • Ms. Carman Alenson CPA (Age 58)
    M.B.A., Senior VP of Finance & Chief Accounting Officer
  • Dr. Jeremy S. Duffield M.D. (Age 56)
    Ph.D., Chief Scientific Officer
    Comp: $994.4k
  • Dr. Karen Brown J.D.
    Ph.D., Senior Vice President of Intellectual Property & Legal Affairs

PRME Stock Analysis - Frequently Asked Questions

Should I buy or sell Prime Medicine stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRME shares.
View PRME analyst ratings
or view top-rated stocks.

What is Prime Medicine's stock price target for 2024?

7 brokers have issued 1-year price objectives for Prime Medicine's shares. Their PRME share price targets range from $9.00 to $26.00. On average, they predict the company's stock price to reach $17.57 in the next year. This suggests a possible upside of 151.0% from the stock's current price.
View analysts price targets for PRME
or view top-rated stocks among Wall Street analysts.

How have PRME shares performed in 2024?

Prime Medicine's stock was trading at $8.86 on January 1st, 2024. Since then, PRME stock has decreased by 21.0% and is now trading at $7.00.
View the best growth stocks for 2024 here
.

When is Prime Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PRME earnings forecast
.

How were Prime Medicine's earnings last quarter?

Prime Medicine, Inc. (NYSE:PRME) released its quarterly earnings results on Friday, March, 1st. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.08.

What ETFs hold Prime Medicine's stock?
When did Prime Medicine IPO?

Prime Medicine (PRME) raised $175 million in an IPO on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share.

Who are Prime Medicine's major shareholders?

Prime Medicine's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.17%), Vanguard Group Inc. (3.38%), Sumitomo Mitsui Trust Holdings Inc. (3.62%), Nikko Asset Management Americas Inc. (3.62%), ARK Investment Management LLC (3.22%) and Price T Rowe Associates Inc. MD (2.28%). Insiders that own company stock include 2019 Gp LLC Gv and Robert Nelsen.
View institutional ownership trends
.

How do I buy shares of Prime Medicine?

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PRME) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners